Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Immunohistochemistry [2]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF805 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal Osteoprotegerin/TNFRSF11B Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse Osteoprotegerin is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references Differential expression patterns of Toll Like Receptors and Interleukin-37 between calcific aortic and mitral valve cusps in humans.
Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability.
Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain.
Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets.
Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Kapelouzou A, Kontogiannis C, Tsilimigras DI, Georgiopoulos G, Kaklamanis L, Tsourelis L, Cokkinos DV
Cytokine 2019 Apr;116:150-160
Cytokine 2019 Apr;116:150-160
Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability.
Davaine JM, Quillard T, Brion R, Lapérine O, Guyomarch B, Merlini T, Chatelais M, Guilbaud F, Brennan MÁ, Charrier C, Heymann D, Gouëffic Y, Heymann MF
PloS one 2014;9(9):e107642
PloS one 2014;9(9):e107642
Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain.
Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M, Suzawa T, Hoshino M, Imamura T, Akiyama C, Yasuhara R, Mishima K, Maruyama T, Kohda C, Tanaka K, Potempa J, Yasuda H, Baba K, Kamijo R
The Journal of biological chemistry 2014 May 30;289(22):15621-30
The Journal of biological chemistry 2014 May 30;289(22):15621-30
Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets.
Chollet ME, Brouland JP, Bal dit Sollier C, Bauduer F, Drouet L, Bellucci S
British journal of haematology 2010 Mar;148(5):805-7
British journal of haematology 2010 Mar;148(5):805-7
Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I
International journal of cancer 2006 Apr 15;118(8):1901-8
International journal of cancer 2006 Apr 15;118(8):1901-8
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
The American journal of pathology 2003 Nov;163(5):2021-31
The American journal of pathology 2003 Nov;163(5):2021-31
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
The American journal of pathology 2003 Nov;163(5):2021-31
The American journal of pathology 2003 Nov;163(5):2021-31
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Osteoprotegerin/TNFRSF11B in Human Lymph Node. Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using 15 µg/mL Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Osteoprotegerin/TNFRSF11B in Human Lymph Node. Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific labeling was localized to the cytoplasm and plasma membrane of lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human Osteoprotegerin/TNFRSF11B Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human Osteoprotegerin/TNF-RSF11B (Catalog # 185-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/ TNFRSF11B (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Osteoprotegerin/ TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805). The ND50 is typically 0.25-0.7 µg/mL.